Lilly to make generic insulin available at half of Humalog’s current price

Eli Lilly & Co. LLY, +2.02% said Monday it will introduce a generic version of Humalog insulin in the U.S., at a price that’s half the current list price. The lower priced version, called insulin Lispro, has the same molecule as Humalog and will be available in vial and pen options. A single vial will be priced at $137.35, while a KwikPens five pack will be $265.20. The lower-priced insulin will be made available in pharmacies “as quickly as possible.” Humalog will also remain available. “”Solutions that lower the cost of insulin at the pharmacy have been introduced in recent months, but more people need help,” said Lilly Chief Executive David Ricks. “We’re eager to bring forward a low-priced rapid-acting insulin.” Lilly’s stock, which is still inactive in premarket trade, has run up 67% over the past 12 months, while the S&P 500 SPX, +0.69% has gained 4.2%.

https://www.marketwatch.com/story/eli-lilly-to-make-generic-insulin-available-at-half-of-humalogs-current-price-2019-03-04